Overview

A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Status:
Completed

Trial end date:
2020-11-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether Nivolumab is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

Ono Pharmaceutical Co. Ltd

Treatments:

Antibodies, Monoclonal
Nivolumab